Theravax‾² vaccine. RVx is planning clinical trials of our live-attenuated therapeutic HSV-2 vaccine, which the published literature indicates is about 40 – 100 times more effective than any of HSV-2 subunit type vaccines developed over the past 30 years.
@Maybe1day These are not incompatible and you're reading too much into what he is saying if you think he is promising a lot more than this - what he is actually saying.
Now the point I was making is you're not going to replicate levels of antibodies that are produced in prophylactic use when someone already has HSV. I've already seen HSV amplicon use results testing its use with prior HSV infection and its quite clear you get a boost of antibodies and T-cells but its orders of magnitude lower than someone who's immune system has never seen HSV. I would think Halford will be able to show the same thing at least and "dial back herpes disease symptoms" - how much remains to be seen.
I didn't ask him to cite his sources, but he told me he'd look into it and let me know if there was anything different to report. I have to wonder if I would accept the 1:100,000 odds my doc gave me if it were related to pregnancy.
@boricacid, while true it's not the end of the world, contracting it would potentially limit any further opportunities for a relationship should this one fizzle.
This article was referenced in another thread by @Clearme but it's another positive study in terms of methods of delivery, in this case AAV. It at least shows that progress continues to be made and maybe this can be used for CRISPR someday in the near future.
Adeno-associated virus (AAV) has been shown to transduce dorsal root ganglion sensory neurons following direct intraganglionic sciatic nerve injection and intraperitoneal and intravenous injection as well as intrathecal injection. We sought to determine if rAAV vectors would be delivered to the same sensory neurons that herpes simplex virus (HSV-1) infects when applied peripherally at an epithelial surface that had been treated to expose the underlying sensory nerve termini.
We demonstrated that this method of inoculation can achieve a transduction rate of >90% of the sensory neurons in the DRG that innervate the footpad. Similarly, we showed that corneal inoculation with rAAV vectors in the rabbit efficiently transduced >70% of the TG neurons in the optic tract. Finally, we demonstrated that coinfection of mouse footpads or rabbit eyes with rAAV vectors and HSV-1 resulted in colocalization in nearly all of the HSV-1-positive neurons. These results suggest that rAAV is a useful tool for the study of HSV-1 infection and may provide a means to deliver therapeutic cargos for the treatment of HSV infections or of dysfunctions of sensory ganglia.
@OhFuckMyDickHurts this is more in line with what you said would be an efficient delivery of crispr, and seeing Dr. Blooms name in there is probably a good sign for Cullen's studies. The article never mentioned crispr but if they can make this work with it, this could be a breakthrough and not be as dangerous.